...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Febrile neutropenia, colony-stimulating factors and therapy: time for a new methodology?
【24h】

Febrile neutropenia, colony-stimulating factors and therapy: time for a new methodology?

机译：发热性中性粒细胞减少，集落刺激因子和治疗：是时候采用新方法了吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The utilization of granulocyte colony-stimulating factors (G-CSF) in febrile neutropenia has been controversial for many years. Berghmann et al.'s meta-analysis again demonstrates that G-CSF does not have an impact on mortality in febrile neutropenia, because the depth and duration of neutropenia in the trials are variable. Also, with mortality from febrile neutropenia less than 15%, any further study would require a vast number of patients to demonstrate a difference in mortality. The Elting and Cantor review provides a new paradigm to studies in patients with febrile neutropenia. These authors recognize that cost, quality of life, life-years gained and adverse events experienced with new therapies should be evaluated, in addition to the standard measures of infection resolution and related mortality. Therefore, for the evaluation of new therapeutic interventions, a consensus on stratified risk factors or the use of an already established model could provide end-points with comparable measurements.
机译：发热性中性粒细胞减少症中粒细胞集落刺激因子（G-CSF）的利用已引起争议。 Berghmann等人的荟萃分析再次证明，G-CSF对发热性中性粒细胞减少症的死亡率没有影响，因为试验中中性粒细胞减少症的深度和持续时间是可变的。此外，由于发热性中性粒细胞减少症的死亡率低于15％，因此任何进一步的研究都将需要大量的患者证明死亡率的差异。 Elting and Cantor综述为高热性中性粒细胞减少症患者的研究提供了新的范例。这些作者认识到，除了应对感染的标准方法和相关死亡率外，还应评估新疗法的成本，生活质量，获得的寿命和不良事件。因此，为了评估新的治疗干预措施，就分层风险因素达成共识或使用已经建立的模型可以为终点提供可比的测量结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号